(Q38035043)

English

Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials

scientific article published on 08 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

0 references

Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

author name string

Xiao-Jun Xu

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Hai-Zhao Zhao

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Yong-Min Tang

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

publication date

8 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

255-260

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Mechanisms of immune evasion by tumors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Treatment of advanced leukemia in mice with mRNA engineered T cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

CARs on track in the clinic

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4(+) T cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Resistance of mature T cells to oncogene transformation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.715350

21 January 2018

Identifiers

10.3109/10428194.2012.715350

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38035043&oldid=1749491442"